NovMetaPharma Co., Ltd. (XKON: 229500)

Market Cap	46.88B
Revenue	n/a
Net Income	n/a
Shares Out	8.96M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,916
Open	5,600.00
Previous Close	5,500.00
Day's Range	5,330.00 - 5,600.00
52-Week Range	4,505.00 - 10,250.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 229500